Global Head of Project Management

Director/Senior Director, Head of Medical Affairs

Director/Senior Director, Clinical Development

VP/SVP, Head of Clinical Development

Don't see a perfect job? Apply opportunistically.

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.

<p>Jnana Therapeutics specializes in discovering and developing medicines to expand the universe of therapeutic impact. By combining deep drug discovery, development expertise and their proprietary technology, Jnana is unlocking highly validated but previously undruggable targets. Drug discovery involves use of Jnana’s chemoproteomic platform, Reactive Affinity Probe Interaction Discovery (RAPID), a proprietary ligand platform to identify small molecule binders irrespective of the target. The unbiased approach of RAPID allows challenging targets, such as transcription factors and helicases, to be investigated. By using their RAPID platform, Jnana is developing a pipeline targeting many rare genetic diseases, immune-mediated diseases and oncology.  </p>


Find a biotech startup job.